More NewsRead More
University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer Trial
September 10, 2014
Small companies lead the I-O class of Cancer Therapies
August 08, 2014
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
September 03, 2014
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
August 19, 2014
CEL-SCI Has Been Cleared to Begin Patient Enrollment
July 23, 2014
Review on Biotech Stocks -- Incyte, ACADIA Pharma, Cel-Sci, Aegerion Pharma, and ImmunoGen
July 18, 2014
from PR Newswire
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial
August 01, 2014
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here